Peroxin Drug: A Developing Treatment for Genetic Disease

Peroxin-targeted drugs represent a family of experimental therapies aimed at rescuing the function of peroxisomes, tiny cellular compartments whose malfunction causes devastating genetic conditions collectively known as peroxisome biogenesis disorders. No approved peroxin drug exists yet, but several strategies are moving through preclinical testing, from small molecules that stabilize misfolded peroxin proteins to gene therapies that deliver working copies of the faulty gene directly into affected tissues. The science is still early, but the pace of discovery has picked up considerably over the past decade, giving families affected by these rare diseases reason for cautious hope.

What Peroxins Do and Why They Matter

Peroxisomes are small membrane-bound structures found in nearly every cell. They handle a range of metabolic jobs, including breaking down very-long-chain fatty acids and producing plasmalogens, a class of fats critical for brain and nerve cell membranes.¹ Building and maintaining peroxisomes requires a set of proteins called peroxins, encoded by PEX genes. When any of these PEX genes carries a harmful mutation, the peroxisome either fails to form properly or cannot import the enzymes it needs to work. The result is a buildup of toxic fatty acids and a shortage of essential lipids, which together damage the brain, liver, kidneys, and eyes.

The most severe of these conditions is Zellweger syndrome, in which peroxisomes are virtually absent. At the milder end sits a range of conditions sometimes grouped under the label Zellweger spectrum disorder (ZSD). More than a dozen different PEX genes have been linked to these disorders, and the clinical picture depends on which gene is affected and how severely its protein is disrupted. Mutations in PEX1 account for roughly two-thirds of all cases, with one specific missense change (PEX1-G843D) being the single most common disease-causing variant. Other genes, such as PEX19 and PEX26, are rarer culprits but cause equally serious outcomes.²

Why Standard Medicine Has Struggled

Most peroxisome biogenesis disorders are inherited in an autosomal recessive pattern, meaning a child must receive a defective copy of the same PEX gene from each parent. These conditions are individually rare, and the combined incidence is estimated at roughly one in 50,000 births. That rarity has historically made them unattractive to drug developers. The Orphan Drug Act, which incentivizes treatments for rare diseases, has helped somewhat: among inborn errors of metabolism, disorders involving complex molecules (the category that includes peroxisomal disorders) have received more orphan drug designations than other subgroups. But approvals remain sparse. A review of orphan product designations from 1983 through 2008 found that lysosomal storage diseases led the way with nine approved products, while mitochondrial diseases and peroxisomal disorders lagged far behind.³

Beyond the economics, the biology itself is challenging. Peroxisomal disorders affect multiple organ systems simultaneously. A drug that reaches the liver may do nothing for the brain. A therapy that works for one PEX gene mutation may be useless for another. These hurdles explain why the drug development pipeline has produced multiple distinct approaches rather than a single “peroxin drug.”

Pharmacological Chaperones for Misfolded Peroxins

The most advanced small-molecule strategy targets the PEX1-G843D mutation specifically. This mutation does not eliminate the PEX1 protein entirely; it produces a full-length protein that folds incorrectly and gets degraded before it can do its job. The idea behind pharmacological chaperone therapy is simple: find a small molecule that binds the misfolded protein, helps it hold its shape, and gives it enough stability to function. Researchers screened chemical libraries and identified four compounds that partially restored peroxisome protein import in patient-derived cells.⁴ Three of those compounds held up in follow-up testing, confirming that the misfolded PEX1 protein is, in principle, rescuable.

Later work zeroed in on naturally occurring flavonoids as potential chaperones. Diosmetin, a plant-derived compound found in citrus fruits, improved the stability and function of the PEX1/PEX6 protein complex in fibroblasts from Zellweger spectrum disorder patients carrying the PEX1-G843D allele.⁵ Flavonoids are appealing because they have a long track record of safety in humans at dietary levels, which could simplify the path toward clinical testing. Still, jumping from a cell dish to a human patient involves enormous uncertainty, and no chaperone compound has yet entered formal clinical trials for ZSD.

One important limitation: chaperone therapy only works when there is a protein to rescue. Patients whose mutations completely prevent production of a peroxin protein, such as those with nonsense mutations or large gene deletions, would not benefit from this approach. That narrows the eligible population, though the PEX1-G843D mutation is common enough that even a narrowly targeted therapy could help a meaningful number of patients.

Nonsense Suppression as a Different Angle

Some patients carry nonsense mutations, DNA changes that insert a premature stop signal into the gene and produce a truncated, nonfunctional protein. Drugs called readthrough agents can trick the cell’s protein-making machinery into ignoring that premature stop signal, allowing a full-length protein to be produced. Two such agents, the aminoglycoside G418 (geneticin) and the compound ataluren, have been tested in cells from patients with nonsense mutations in the PEX2 and PEX12 genes. G418 treatment produced dramatic improvements in very-long-chain fatty acid breakdown and plasmalogen production, and imaging confirmed that peroxisome assembly improved as well.⁶

Readthrough therapy faces its own set of constraints. Not all nonsense mutations respond equally, because the identity of the premature stop codon and the surrounding genetic sequence both influence how readily the drug can bypass the stop signal. Aminoglycosides like G418 also carry toxicity concerns at the doses needed for effective readthrough, particularly to the kidneys and inner ear. Ataluren was designed to be less toxic, though its clinical performance in other diseases has been mixed. For peroxisomal disorders specifically, readthrough therapy remains at the cell-culture stage.

Peroxisome Proliferators and Phenylbutyrate

A different strategy sidesteps the faulty protein altogether and asks: can you simply make more peroxisomes? Sodium 4-phenylbutyrate, a drug already approved for another metabolic condition (urea cycle disorders), acts as a peroxisome proliferator in human cells. When applied to fibroblasts from patients with peroxisome biogenesis disorders, it roughly doubled the number of peroxisomes. In cells from patients with milder forms of ZSD (historically called neonatal adrenoleukodystrophy and infantile Refsum disease), phenylbutyrate treatment increased very-long-chain fatty acid breakdown, boosted plasmalogen levels, and reduced toxic fatty acid accumulation. Cells from patients with the most severe form, classic Zellweger syndrome, did not show these metabolic improvements.⁷

The selective response makes biological sense. In the mildest cases, peroxisomes exist but work poorly. Increasing their number gives the cell more partially functional organelles, and the aggregate improvement can be enough to restore near-normal metabolism. In the most severe cases, peroxisomes are so fundamentally broken that making more of them simply multiplies the dysfunction. This distinction matters for clinical strategy: phenylbutyrate and similar proliferators are probably best suited for a subset of patients at the milder end of the disease spectrum.

Researchers have also built high-throughput screening systems to discover new peroxisome proliferators beyond phenylbutyrate. One group designed a cell-based assay using a genetically encoded fluorescent reporter that lights up when peroxisome number increases, allowing them to sift through large chemical libraries efficiently.⁸ The hope is that newer compounds might be more potent or produce fewer side effects than phenylbutyrate, which can cause nausea and a strong body odor at therapeutic doses.

Gene Therapy Enters the Picture

Gene augmentation therapy takes the most direct approach: deliver a working copy of the defective PEX gene into the patient’s cells. The challenge has always been getting the gene to the right tissues, in the right amount, without triggering immune reactions or other harm. The first proof-of-concept studies have focused on the eye, a relatively accessible organ that is severely affected in ZSD and serves as a useful test bed for broader gene therapy development.

In a mouse model carrying the murine equivalent of the common human PEX1-G843D mutation, researchers injected an adeno-associated virus (AAV) vector carrying the human PEX1 gene beneath the retina. The results were encouraging. Toxic fatty acid levels in the retina partially normalized, and retinal electrical responses, measured by electroretinography, improved roughly two-fold compared to control-injected eyes. That improvement held and even increased over time, with treated eyes still showing about double the retinal response of untreated eyes at 32 weeks of age.⁹ No gross side effects were observed at the tissue level.

A follow-up study refined the approach with a redesigned, clinically relevant version of the AAV8-delivered PEX1 gene therapy and tested a range of doses. The improvements were broader and more durable: functional vision, photoreceptor structure, and retinal pigment epithelium integrity all showed marked gains lasting at least six months after a single injection.¹⁰ These studies represent the first application of gene augmentation to any peroxisome biogenesis disorder and lay groundwork for eventual human trials.

The eye-first strategy has practical logic. Retinal gene therapies have an established track record in other inherited eye diseases, and the eye is partially immune-privileged, which reduces the risk of the body attacking the viral vector. But ZSD affects far more than the eyes, and delivering gene therapy to the brain, liver, and kidneys poses far harder delivery problems that remain unsolved for this disease family.

The Mouse Model That Made Testing Possible

Much of the preclinical progress described above depends on a single animal model: the Pex1-G844D knock-in mouse, engineered to carry the mouse equivalent of the most common human PEX1 mutation. These mice develop many of the hallmarks seen in milder human ZSD cases, including growth retardation, fatty liver with cholestasis, and retinal degeneration. Their cells also respond to chaperone-like compounds in the same way patient cells do, with normalization of peroxisomal fatty acid breakdown.¹¹

Before this model existed, researchers were largely confined to cell-culture experiments and a small number of knockout mice with complete peroxisome loss, which mimic only the most severe, typically fatal form of ZSD. Having a mouse that represents the milder, longer-surviving patient population was a turning point. It allows researchers to test whether an intervention that rescues cells in a dish actually improves organ function in a living animal, and it makes it possible to study long-term outcomes in a way that cell cultures never can.

PPAR Agonists and the Brain Barrier

One of the thorniest problems in treating peroxisomal disorders is reaching the brain. The blood-brain barrier blocks most drugs, and neurological damage in ZSD begins early and progresses relentlessly. Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors that regulate genes involved in fat metabolism, inflammation, and peroxisome function. Agonists of these receptors have been explored as neuroprotective agents across multiple neurodegenerative conditions.

Leriglitazone, a brain-penetrant PPARγ agonist, has attracted attention for its potential in X-linked adrenoleukodystrophy, a related peroxisomal disorder. Studies in disease models showed that leriglitazone could modulate multiple biological pathways relevant to neuroinflammation and neurodegeneration.¹² Whether similar PPAR-based strategies could help ZSD patients remains an open question, but the principle is significant: if a small molecule can cross the blood-brain barrier and upregulate peroxisome-related genes in neurons, it could address the neurological damage that no current therapy touches. Leriglitazone has advanced further into clinical development than any chaperone or readthrough agent for peroxisomal disease, though its primary target disease is adrenoleukodystrophy rather than ZSD specifically.

Nutritional Interventions as Bridges

While disease-modifying drugs remain experimental, clinicians have tried nutritional strategies to partly compensate for what broken peroxisomes cannot produce. One early approach involves supplementing patients with docosahexaenoic acid (DHA), an omega-3 fatty acid that peroxisomes normally help synthesize. The rationale is straightforward: if the body cannot make enough DHA, supplying it externally might reduce some of the downstream damage, particularly in the brain and retina. Clinical observations suggest that treatment should start as early as possible, before irreversible organ damage sets in.¹³

Another approach has been glycerol ether lipid supplementation, intended to bypass the plasmalogen deficiency caused by missing peroxisomal enzymes. Early case reports showed that erythrocyte plasmalogen levels increased in a patient with a milder form of Zellweger syndrome after supplementation, and no toxicity was observed. These nutritional strategies do not fix the underlying peroxisome defect, but they may slow certain aspects of disease progression and buy time while disease-modifying therapies mature.

Newborn Screening and the Race Against Irreversible Damage

A recurring theme in peroxisomal disorders is that damage accumulates quickly. Brain myelination, liver function, and retinal development are all affected in the first months and years of life. By the time a child is diagnosed through clinical symptoms alone, significant and often permanent harm has already occurred. This makes early detection critical for any future therapy to have its best chance of working.

Newborn screening for peroxisomal disorders has historically been absent from most screening panels, but recent work has shown that it is technically feasible. A dried blood spot method can detect disease-specific bile acid metabolites associated with Zellweger spectrum disorder, offering a quick and affordable screening approach that could be integrated into existing newborn screening programs.¹⁴ If any of the therapies discussed in this article eventually reach clinical use, the availability of newborn screening could determine whether they are administered early enough to make a real difference.

Why There Is No Single “Peroxin Drug”

The phrase “peroxin drug” is more of a category than a single product. The diversity of PEX gene mutations, the range of disease severity, and the challenge of reaching multiple organ systems all mean that the eventual treatment landscape will likely involve a combination of approaches rather than one pill or one injection. A patient with the PEX1-G843D missense mutation might benefit from a chaperone compound. A patient with a nonsense mutation in PEX2 might need a readthrough agent. A patient with progressive retinal degeneration might be a candidate for localized gene therapy in the eye, while also receiving a PPAR agonist or peroxisome proliferator to address liver and brain disease.

This combinatorial reality is not unique to peroxisomal disorders. Cystic fibrosis treatment has evolved along similar lines, with different drugs targeting different mutation classes and combination regimens becoming standard. For peroxisomal disease, the field is much earlier in that arc, but the shape of the path is becoming visible. The biggest gap right now is the jump from laboratory results to human trials. Cell culture and mouse experiments can demonstrate that a concept works in principle, but the distance from there to a safe, effective therapy in a child is vast and expensive to cross, especially for diseases this rare.

The Role of Genome Editing

Gene augmentation, the approach used in the retinal studies described above, adds a working gene without fixing the original mutation. Precision genome editing tools could theoretically correct the mutation itself, offering a more permanent and potentially more complete fix. Interest in applying CRISPR and related technologies to peroxisomal disorders has grown, and the topic has drawn attention in high-profile medical journals. However, the practical hurdles are formidable. Editing genes in enough cells across enough tissues to reverse a systemic metabolic disorder is beyond what current genome editing platforms can reliably achieve. For the foreseeable future, gene augmentation delivered to specific organs remains the more tractable gene-based approach, while genome editing stays on the horizon as a longer-term aspiration.

What makes peroxisomal disorders an interesting case for genome editing is the nature of the most common mutations. The PEX1-G843D change is a single nucleotide substitution, the simplest possible target for a base editor or prime editor. If delivery challenges are eventually solved for other single-gene diseases, the same technology could in principle be applied to ZSD with relatively little additional development. Whether that happens within the next decade or the next several decades depends on progress in the broader gene editing field more than on anything specific to peroxisomes.